FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Pfizer Glipizide XL Recall

Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx only Distr…

Pfizer Inc. · New York, NY

Risk level
Class II
Reported by FDA
Oct 17, 2018
Recall ID
D-0010-2019
Check your lot numberHow we source this data

Summary

Pfizer recalled Glipizide XL starting Sep 20, 2018. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0010-2019 on Oct 17, 2018. Reason: CGMP Deviations; rejected product was used to manufacture final bulk lot. Status: Terminated.

Why it was recalled

CGMP Deviations; rejected product was used to manufacture final bulk lot

Product description

Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx only Distributed by: Greenstone LLC. Peapack, NJ 07977 --- NDC 59762-0541-2

Lot numbers, UPCs & expiration codes

Lot: T71137 Exp. Feb. 2022

Where it was sold

Nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0010-2019
Classification
Class II
Status
Terminated
Recall initiated
Sep 20, 2018
FDA report date
Oct 17, 2018
Quantity
7777 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Pfizer Inc.

Original FDA data

Every field from FDA enforcement report D-0010-2019, exactly as published.

Show all FDA fields
City
New York
State
NY
Status
Terminated
Country
United States
Event ID
81028
Address
235 E 42nd St
Code information
Lot: T71137 Exp. Feb. 2022
Postal code
10017-5703
Report date
Oct 17, 2018
Product type
Drugs
Recall number
D-0010-2019
Classification
Class II
Recalling firm
Pfizer Inc.
Product quantity
7777 bottles
Termination date
May 8, 2020
Reason for recall
CGMP Deviations; rejected product was used to manufacture final bulk lot
Voluntary / mandated
Voluntary: Firm initiated
Product description
Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx only Distributed by: Greenstone LLC. Peapack, NJ 07977 --- NDC 59762-0541-2
Distribution pattern
Nationwide
Recall initiation date
Sep 20, 2018
Initial firm notification
Letter
Center classification date
Oct 9, 2018

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0010-2019, published Oct 17, 2018. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls